Massachusetts Institute of Technology

Glaxosmithkline Intellectual Property Development Limited

David Lai

Neil Adam Gershenfeld

Andreas Mershin

Filippos Touriomousis

The invention comprises a novel modular, generalizable meso-micro-nano-fluidic platform apparatus, design and methodology which in exemplary embodiments may be applied in conjunction with a novel external triggering and automation/feedback loop control mechanism deployed via computer to explore the phase space of single or double emulsification for applications including the encapsulation of hydrophilic active pharmacological ingredients (APIs). End use applications include the mass production of particulate encapsulation of hydrophobic or hydrophilic APIs with automatic or user-supervised feedback methodology to control and discover mass production or per-drug customized settings of interest for the manufacture of novel or extant therapeutics. This invention allows for a process to produce monodispersed particles of varying sizes and may be used to rapidly screen for optimal size for maximal bioavailability of API particles either on lab bench for in vitro dissolution or in vivo studies, and patient-specific handhelds for maximal drug inhalation.

Growing community of inventors

Philadelphia, PA, United States of America

David Lai